生血宁片联合促红细胞生成素治疗维持性血液透析患者肾性贫血的临床观察

Effect of Shengxuening tablets combined with erythropoietin treatment maintained clinical observation of hemodialysis patients with renal anemia

目的探讨生血宁片联合促红细胞生成素治疗维持性血液透析患者肾性贫血的临床效果。方法选取该院住院治疗的维持性血液透析肾性贫血患者60例,随机分为治疗组与对照组,治疗组患者给予促红细胞生成素联合生血宁片进行治疗,对照组患者给予促红细胞生成素联合蔗糖铁进行治疗。对两组患者治疗前后的贫血指标、临床治疗效果和不良反应进行对比分析。结果两组患者在治疗前的贫血指标之间差异无统计学意义(P>0.05),治疗后两组患者的贫血指标较治疗前有显著变化(P<0.05),治疗组患者治疗后较对照组贫血指标差异有统计学意义(P<0.05)。对照组患者通过治疗后的临床总有效率低于治疗组,两组之间差异有统计学意义(P<0.05)。对照组患者的不良反应率高于治疗组,两组患者之间差异有统计学意义(P<0.05)。对照组患者所使用的促红细胞生成素剂量明显高于治疗组,两组之间差异有统计学意义(P<0.05)。结论采取生血宁片联合促红细胞生成素治疗维持性血液透析患者肾性贫血的临床效果较为良好,且安全性较高,值得在临床治疗中应用。

Objective To investigate the effect of Shengxuening tablets combined with erythropoietin therapy maintained blood clinical effect of dialysis patients with renal anemia. Methods choose the treatment of maintenance hemodialysis patients with re-nal anemia in 60 cases in our hospital, were randomly divided into treatment group and control group, patients in the treatment group were given erythropoietin combined with Shengxuening tablets for treatment, the control group were treated with erythropoi-etin combined with iron sucrose in the treatment. Comparative analysis of two groups of patients before and after anemia index, clinical curative effect and adverse reaction. Results there were no significant differences between the two groups before treatment of anemia of index patients, P 〉 0.05, after treatment, two groups of patients with anemia index compared with those before treat-ment changes significantly, P 〈 0.05, patients in the treatment group than the control group after treatment of anemia index have significant difference, P 〈 0.05. Patients in the control group after treatment by clinical total effective rate than the treatment group, there was significant difference between the two groups, P 〈 0.05. The control group of patients with adverse reaction rate higher than the treatment group, there was significant difference between the two groups of patients, P 〈 0.05. Control erythropoi-etin use groups of patients with hormone dose was significantly higher than the treatment group, there was significant difference be-tween the two groups, P〈0.05. Conclusion take Shengxuening tablets combined with erythropoietin for maintaining blood dialysis patients with renal anemia clinical effect is good, and the safety is high, it is worthy of application in clinical treatment.